PFE Stock Recent News

Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, which includes development of cardiovascular and obesity medicines.

The Investment Committee debates their Final Trades.

PHILADELPHIA, March 05, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. (“Pfizer” or the “Company”) (NYSE: PFE) about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to Pfizer and its shareholders in connection with the Company's marketing and sale of Depo-Provera.

A German court in Duesseldorf on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna.

Pfizer's revenue has stabilized, and operational efficiency is improving, supporting a "Strong buy" rating with a 6.5% forward dividend yield. The market sentiment in the next few months is likely to be quite positive for Pfizer, as the optimism around growth stocks is fading. Patent cliff risks exist, but Pfizer's substantial R&D investments and solid fundamentals make it a compelling high-yield investment.

Hyperinflation and high interest rates make dividend-paying stocks attractive, providing cash flow and alleviating inflation pressure. Pfizer's 6% yield is appealing despite recent stock declines, with a low forward multiple and management's commitment to maintaining dividends. Cost savings and Haleon share sales should support Pfizer's dividend yield, with free cash flow expected to improve next year.

If you want to generate significant long-term gains in the stock market, one place to start looking for investments is among the companies that Wall Street isn't all that thrilled with today. In the short term, these may not be good performers, and they may not have looked like great buys in recent months or years.

Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the discount bin. However, even in a bull market, like the one we're currently experiencing, it's possible to find attractive companies to invest in at attractive prices.

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing 530% to $0.63. Despite modest 2025 guidance, Pfizer's oncology and anti-obesity drugs present growth potential, countering analysts' low expectations. However, risks remain, which include political challenges and patent expirations.

Pfizer's CEO said he may move manufacturing back to the US in response to Donald Trump's tariffs. Albert Bourla said he was not surprised by Trump's victory in November.